Buy CUE by Jun 23, 2027.

Been digging into **Cue Biopharma ($CUE)** and it looks like an interesting small-cap biotech setting up for several potential catalysts over the next 6-12 months. **What they do:** Cue is developing precision immunotherapies designed to selectively activate or regulate immune responses across cancer, autoimmune, and allergic diseases. Rather than being a one-asset story, they’re building a broader immunology platform with multiple programs in development. **Recent developments that caught my attention:** ✅ Potential **$345M partnership** with Boehringer Ingelheim ✅ Received a …